(PRESS RELEASE) VIENNA, 24-Sep-2020 — /EuropaWire/ — Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity … Read the full press release →
Posted in Austria, European Union, France, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science, United Kingdom
Tagged biotechnology, CEBINA, Central European Biotech Incubator and Accelerator, clinical testing, Clinical Trail, Diarrhoeal diseases, Enterotoxigenic E. coli, ETEC, European Vaccine Initiative, Eveliqure, Eveliqure Biotechnologies, Eveliqure Biotechnologies GmbH, Frank Malinoski, Gábor Somogyi, Healthcare, Horizon 2020, icddr b, PATH, Pharma & Biotech, science, Shigella, ShigETEC, SHIGETECVAX, Travel Diarrhea, University of Gothenburg, vaccine candidate, Wellcome Trust